- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04772365
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects
November 28, 2022 updated by: Shanghai Hengrui Pharmaceutical Co., Ltd.
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered SHR-1819 in Healthy Subjects
This is a single center, randomized, double-blind, placebo-controlled, single and multiple dose escalation phase 1 study.
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous administered SHR-1819 in healthy subjects
Study Overview
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Changsha
-
Changsha, Changsha, China, 410013
- The Third Xiangya Hospital of Central South University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written informed consent.
- Be able to comply with all the requirements and able to complete the study.
- Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
- No clinically significant abnormalities in medical history, general physical examination, vital signs, and laboratory tests.
- Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods and have no plan to have a child from signing the consent form to 16 weeks after IP administration.
Exclusion Criteria:
- Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency virus (HIV-Ab), or QuantiFERON-TB Gold tests at screening;
- Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening (according to the date of signed consent form), or in the follow-up period of a clinical study
- Severe injuries or surgeries within 6 months before screening or plan to do surgeries during the trial
- Any other circumstances that, in the investigator's judgment, may increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment group A
|
SHR-1819 will be subcutaneously administered with different dose levels;
|
PLACEBO_COMPARATOR: Treatment group B
|
Placebo will be subcutaneously administered with different dose levels;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Start of Treatment to end of study(about 13 weeks)
|
Incidence and severity of adverse events
|
Start of Treatment to end of study(about 13 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics-AUC0-inf
Time Frame: Start of Treatment to end of study (approximately 13 weeks)
|
Area under the concentration-time curve from time 0 to infinity after SHR-1819 administration
|
Start of Treatment to end of study (approximately 13 weeks)
|
Pharmacokinetics-Tmax
Time Frame: Up to 13 weeks
|
Time to Cmax of SHR-1819
|
Up to 13 weeks
|
Pharmacokinetics-Cmax
Time Frame: Up to 13 weeks
|
Maximum observed concentration of SHR-1819
|
Up to 13 weeks
|
Pharmacokinetics-CL/F
Time Frame: Up to 13 weeks
|
Apparent clearance of SHR-1819
|
Up to 13 weeks
|
Pharmacokinetics-Vz/F
Time Frame: Up to 13 weeks
|
Apparent volume of distribution during terminal phase of SHR-1819
|
Up to 13 weeks
|
Pharmacokinetics-t1/2
Time Frame: Up to 13 weeks
|
Terminal elimination half-life of SHR-1819
|
Up to 13 weeks
|
Change from baseline to end of treatment for IgE
Time Frame: Up to 13 weeks
|
IgE
|
Up to 13 weeks
|
Pharmacokinetics-AUC0-last
Time Frame: Start of Treatment to end of study (about 13 weeks)
|
Area under the concentration-time curve from time 0 to last time point after SHR-1819 administration
|
Start of Treatment to end of study (about 13 weeks)
|
Change from baseline to end of treatment for Thymus and activation-regulated chemokine(TARC/CCL17)
Time Frame: Up to 13 weeks
|
Thymus and activation-regulated chemokine(TARC/CCL17)
|
Up to 13 weeks
|
Immunogenicy of SHR-1819 after administration
Time Frame: Up to 13 weeks]
|
Anti-drug antibody
|
Up to 13 weeks]
|
Pharmacokinetics-AUCtau for multi-dose
Time Frame: Start of Treatment to end of study (about 13 weeks)
|
Area under the concentration-time curve from time 0 to last time point after SHR-1819 administration
|
Start of Treatment to end of study (about 13 weeks)
|
Pharmacokinetics- Ctrough for multi-dose
Time Frame: Up to 13 weeks
|
Minimum observed concentration of SHR-1819
|
Up to 13 weeks
|
Pharmacokinetics- Racc for multi-dose
Time Frame: Up to 13 weeks
|
Accumulation ratio of SHR-1819
|
Up to 13 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 1, 2021
Primary Completion (ACTUAL)
December 10, 2021
Study Completion (ACTUAL)
December 10, 2021
Study Registration Dates
First Submitted
February 22, 2021
First Submitted That Met QC Criteria
February 25, 2021
First Posted (ACTUAL)
February 26, 2021
Study Record Updates
Last Update Posted (ACTUAL)
November 29, 2022
Last Update Submitted That Met QC Criteria
November 28, 2022
Last Verified
February 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- SHR-1819-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on SHR-1819
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Enrolling by invitationModerate to Severe Atopic DermatitisChina
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced MalignanciesAustralia, China
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingAlzheimer's DiseaseChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingAsthma With Eosinophilic PhenotypeChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed HyperlipemiaChina